Cardinal Health FY2026: revenue up 14% to $254.2 billion, EPS lifted by refund
Cardinal Health finished fiscal 2026 with $254.2 billion of revenue, up 14%, and GAAP diluted EPS of $7.23 against $11.26 on a non-GAAP basis. That $4.03 gap is the story: a $100 million tariff refund and a long list of excluded charges separate the two numbers. Think of it as a distributor earning pennies on every dollar of sales — good execution, noisy optics.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS for the year was $7.23, up 12.0%, while non-GAAP diluted EPS was $11.26, up 37.0% — a $4.03 gap built from amortization of acquired intangibles, acquisition-related compensation and a $122 million impairment of the Outcomes stake. The fourth quarter's non-GAAP EPS of $2.91 also cleared the $2.4443 consensus estimate, though $0.31 of it was the tariff refund. Excluding that item, full-year non-GAAP EPS was $10.95, still up 33.0%.
Full-year revenue rose 14.0% to $254.2 billion, and the fourth quarter alone brought in $63.7 billion, up 6.0% from a year earlier. Almost all of it — $58.8 billion in the quarter — came from the Pharmaceutical and Specialty Solutions segment. Global Medical Products and Distribution actually shrank 2.0% to $3.1 billion.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.